U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), granting Lee’s exclusive rights to develop, market, and commercialize Renazorb (lanthanum dioxycarbonate) in mainland China, Hong Kong, and other Asian markets.
Licensing Terms
Under the agreement, Unicycive will receive an upfront payment of USD 1 million and up to USD 1 million in milestone payments upon product launch in China. The firm is also eligible for tiered royalties based on regulatory and commercial milestones.
Drug Profile
Renazorb is a novel phosphate binder for hyperphosphatemia in chronic kidney disease (CKD) patients. Its best-in-class profile offers patient adherence benefits, requiring smaller, fewer pills per dose that are swallowed rather than chewed.
Company Background
Unicycive Therapeutics focuses on novel kidney disease treatments. Its pipeline includes Renazorb and UNI-494, a patent-protected drug candidate for acute kidney injury in late preclinical development.-Fineline Info & Tech
